Pharma Stocks

The stock gained 9 per cent in two days after the pharma company reported better-than-expected revenue growth in March quarter (Q4FY22).

The company has earmarked an aggressive capex of around Rs 2,000 crore over next two years in order to take a chunk of around $20 billion opportunity of APIs going off-patent over FY23-25.

In Q4FY22, normalised earnings before interest, taxes, depreciation, and amortization (EBITDA) margins contracted 630 bps to 19.4 per cent from 25.7 per cent in Q4FY21

Analysts at ICICI Securities expect Aurobindo Pharma's adjusted PAT to de-grow 30.4 per cent year-on-year (YoY) to Rs 557.90 crore in the March 2022 quarter.

In the past five days, the stock has fallen over 5 per cent. In comparison, the S&P BSE Sensex declined 3.75 per cent during the same period

Stocks to Watch Today: Shares of pharma company - Aurobindo, Sun Pharma and Jubilant are likely to be in focus as the trio have recalled different products in the US market as per the latest USFDA

The Nifty Pharma index has crossed its near-term resistance at 13,700, and may spurt another 1.5 per cent.

Outlook for Indian drug exporters turned positive on prospects of firm exports amid the ongoing geo-political scenario, said analysts

Progress on US sales will be key for further Torrent Pharma's stock gains

In the past three months, Natco Pharma has outperformed the market by gaining 8 per cent, as compared to 8 per cent decline in the S&P BSE Sensex.

Pharma shares are likely to be in limelight as NPPA may allow up to 10 per cent hike on scheduled drugs in the month of April.

Infinity Holdings Group made an open offer to buy 26 per cent stake in the company at a price of Rs 235 per share

Surging healthcare spending and demand for Covid tests led to multifold share-price gains for pathology firms globally during the pandemic

Chairman Y K Hamied and Vice Chairman MK Hamied, who are non-executive directors and promoters, have sold 2,01,69,756 shares on Tuesday

Biocon said its subsidiary Biocon Pharma has received approval of its ANDA for Posaconazole Delayed-Release tablets from the US FDA.

In Q3FY22, earnings before interest tax and depreciation and amortization (EBITDA) margins declined 490 bps YoY to 25.5 per cent driven by price erosion in the US.

The company believes that this will not impact the existing business from this facility.

The better traction in the specialty segment and improvement in domestic business to drive the margin expansion in Q3.

Pharma shares may be in focus as India's apex health research organization ICMR has raised concerns around the safety for use of the oral antiviral drug Molnupiravir

Reliance Jio plans its biggest ever rupee bond sale, while Bharti Airtel shelves its plans to de-merge its core telecom business